Inclusion Criteria:

          -  Pathologically-confirmed KRAS(G12D-), KRAS(G12V-), KRAS(G12R-) or KRAS(G12C-mutated)
             pancreatic ductal adenocarcinoma who are at high risk of relapse and have no evidence
             of disease.

          -  Expression of one or more of the following HLA class I alleles: HLA-A02, HLA-A03,
             HLA-A11, HLA-B07 and HLA-C08.

          -  Male or female, age 18+

          -  ECOG performance status 0-1

          -  Certain required laboratory values, performed within 14 days prior to consent

          -  Subjects of reproductive potential must agree to use a medically accepted birth
             control method during the trial and for at least two months following the trial.

          -  Provide written informed consent

        Exclusion Criteria:

          -  Prior treatment with more than one line of cytotoxic chemotherapy. Radiotherapy is not
             considered a line of therapy.

          -  Prior malignancy (except non-melanoma skin cancer) within 3 years.

          -  Pregnant or nursing women.

          -  Concurrent treatment with systemic immunosuppressants, including corticosteroids (e.g
             prednisone), calcineurin inhibitors (e.g tacrolimus, cyclosporine), antiproliferative
             agents (e.g mycophenolate mofetil, azathioprine) within 2 weeks of eligibility
             confirmation. Local (inhaled or topical) steroids or replacement dose prednisone (≤ 10
             mg daily) are permitted.

          -  Known chronic viral infections including hepatitis B, hepatitis C, and HIV.

          -  Known allergy to eggs.

          -  Prior history of uveitis or autoimmune inflammatory eye disease.

          -  Uncontrolled intercurrent illness.

          -  Any condition that, in the opinion of the investigator, would interfere with
             evaluation of the investigational product or interpretation of subject safety or study
             results.